Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Target Price at $11.00

Shares of Personalis, Inc. (NASDAQ:PSNL) have been assigned an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.00.

Several research firms have recently issued reports on PSNL. BTIG Research boosted their price target on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Guggenheim raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. Needham & Company LLC boosted their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, February 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd.

Personalis Stock Performance

PSNL stock opened at $6.72 on Wednesday. The stock has a fifty day moving average of $8.81 and a 200-day moving average of $8.19. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50. The company has a market capitalization of $703.11 million, a price-to-earnings ratio of -7.38 and a beta of 2.02.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $17.35 million for the quarter, compared to analysts’ expectations of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. Equities analysts predict that Personalis will post -1.4 EPS for the current year.

Institutional Trading of Personalis

A number of institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its stake in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the period. Legal & General Group Plc bought a new stake in shares of Personalis during the second quarter valued at about $30,000. International Assets Investment Management LLC purchased a new stake in shares of Personalis in the fourth quarter worth about $31,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Personalis in the second quarter worth about $34,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.